Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN)‘s stock had its “neutral” rating reaffirmed by stock analysts at Robert W. Baird in a report released on Monday. They presently have a $145.00 price target on the biopharmaceutical company’s stock. Robert W. Baird’s price target points to a potential upside of 15.92% from the stock’s current price.

A number of other equities research analysts also recently commented on the company. Leerink Swann set a $208.00 target price on Alexion Pharmaceuticals and gave the stock a “buy” rating in a report on Monday, March 13th. Morgan Stanley raised Alexion Pharmaceuticals from an “equal weight” rating to an “overweight” rating and lifted their target price for the stock from $101.08 to $138.00 in a report on Thursday, May 25th. Barclays PLC reaffirmed an “overweight” rating and set a $155.00 target price on shares of Alexion Pharmaceuticals in a report on Tuesday, May 9th. Cowen and Company reaffirmed an “outperform” rating and set a $180.00 target price on shares of Alexion Pharmaceuticals in a report on Friday, April 28th. Finally, Royal Bank Of Canada reaffirmed an “outperform” rating and set a $177.00 target price on shares of Alexion Pharmaceuticals in a report on Monday, March 27th. Eight investment analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has given a strong buy rating to the stock. Alexion Pharmaceuticals has a consensus rating of “Buy” and an average target price of $161.38.

Alexion Pharmaceuticals (NASDAQ:ALXN) traded down 0.78% during trading on Monday, hitting $125.09. 2,916,800 shares of the stock traded hands. Alexion Pharmaceuticals has a 52-week low of $96.18 and a 52-week high of $145.41. The firm has a 50-day moving average price of $112.77 and a 200 day moving average price of $122.35. The company has a market cap of $28.09 billion, a P/E ratio of 59.60 and a beta of 1.45.

Alexion Pharmaceuticals (NASDAQ:ALXN) last released its earnings results on Thursday, April 27th. The biopharmaceutical company reported $1.38 EPS for the quarter, topping the Zacks’ consensus estimate of $1.05 by $0.33. Alexion Pharmaceuticals had a return on equity of 11.72% and a net margin of 14.52%. The firm had revenue of $870 million during the quarter, compared to the consensus estimate of $826.63 million. During the same quarter in the previous year, the company posted $1.11 earnings per share. The company’s revenue was up 24.3% compared to the same quarter last year. On average, equities analysts expect that Alexion Pharmaceuticals will post $5.31 EPS for the current year.

ILLEGAL ACTIVITY WARNING: “Robert W. Baird Reaffirms “Neutral” Rating for Alexion Pharmaceuticals, Inc. (ALXN)” was originally reported by American Banking News and is owned by of American Banking News. If you are viewing this piece of content on another domain, it was illegally copied and republished in violation of U.S. & international copyright and trademark legislation. The legal version of this piece of content can be accessed at https://www.americanbankingnews.com/2017/06/26/robert-w-baird-reaffirms-neutral-rating-for-alexion-pharmaceuticals-inc-alxn.html.

In other Alexion Pharmaceuticals news, CEO Ludwig Hantson acquired 10,000 shares of the business’s stock in a transaction dated Wednesday, June 14th. The stock was acquired at an average cost of $116.72 per share, for a total transaction of $1,167,200.00. Following the completion of the transaction, the chief executive officer now directly owns 38,725 shares of the company’s stock, valued at $4,519,982. The purchase was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director Bros. Advisors Lp Baker acquired 1,348,955 shares of the business’s stock in a transaction dated Wednesday, June 14th. The stock was acquired at an average price of $116.32 per share, with a total value of $156,910,445.60. The disclosure for this purchase can be found here. Insiders bought 2,019,734 shares of company stock valued at $235,606,846 over the last 90 days. Company insiders own 4.35% of the company’s stock.

Several hedge funds have recently bought and sold shares of the stock. Advantage Investment Management LLC acquired a new stake in Alexion Pharmaceuticals during the fourth quarter worth approximately $101,000. Guardian Life Insurance Co. of America boosted its stake in Alexion Pharmaceuticals by 0.7% in the first quarter. Guardian Life Insurance Co. of America now owns 865 shares of the biopharmaceutical company’s stock worth $105,000 after buying an additional 6 shares during the period. Meeder Asset Management Inc. acquired a new stake in Alexion Pharmaceuticals during the first quarter worth approximately $111,000. Independent Portfolio Consultants Inc. boosted its stake in Alexion Pharmaceuticals by 46.9% in the first quarter. Independent Portfolio Consultants Inc. now owns 1,065 shares of the biopharmaceutical company’s stock worth $129,000 after buying an additional 340 shares during the period. Finally, FUKOKU MUTUAL LIFE INSURANCE Co boosted its stake in Alexion Pharmaceuticals by 10.0% in the first quarter. FUKOKU MUTUAL LIFE INSURANCE Co now owns 1,100 shares of the biopharmaceutical company’s stock worth $133,000 after buying an additional 100 shares during the period. Institutional investors and hedge funds own 94.14% of the company’s stock.

Alexion Pharmaceuticals Company Profile

Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).

Analyst Recommendations for Alexion Pharmaceuticals (NASDAQ:ALXN)

Receive News & Ratings for Alexion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.